Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Phosphofructokinase from the Liver Fluke Fasciola hepatica

II. Kinetic Properties of the Enzyme

DEBORAH BENNETT STONE and TAG E. MANSOUR
Molecular Pharmacology March 1967, 3 (2) 177-187;
DEBORAH BENNETT STONE
Department of Pharmacology, Stanford University School of Medicine, Palo Alto, California 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAG E. MANSOUR
Department of Pharmacology, Stanford University School of Medicine, Palo Alto, California 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This paper describes the kinetics of phosphofructokinase from the liver fluke Fasciola hepatica. Activation of the enzyme was accompanied by a marked increase in its affinity for both fructose-6-P and ATP. Results with the activated enzyme showed that each of the three ligands (fructose-6-P, ATP and cyclic 3',5'-AMP) could alter the saturation function of the other. The enzyme was strongly inhibited by ATP in the presence of low fructose-6-P concentrations. Both cyclic 3',5'-AMP and fructose-6-P could increase the concentrations of ATP required to produce 50% inhibition. Possible interaction among the substrates and the effector ligands on the enzyme was considered in terms of the Monod-Changeux-Wyman model for allosteric proteins. Saturation curves for fructose-6-P indicated cooperative homotropic interactions between multiple binding sites for this substrate. ATP at high concentration increased the homotropic interactions while cyclic 3',5'-AMP had the opposite effect. The saturation function of cyclic 3',5'-AMP was also shown to be influenced by both enzyme substrates. Fructose-6-P at high concentration caused a decrease in the half-saturation point for cyclic 3',5'-AMP while ATP had the opposite effect. Saturation curves for Mg++ were also altered by a change in concentration of fructose-6-P, ATP or cyclic 3',5'-AMP. The possible role of these kinetic properties on the fine regulation of activated phosphofructokinase was discussed.

ACKNOWLEDGMENTS This work was supported by Research Grant AI04214 from the National Institute of Allergy and Infectious Diseases, U. S. Public Health Service; and a Research Career Development Award GM-K3-3848 from the Division of General Medical Sciences, U. S. Public Health Service.

  • Copyright ©, 1967, by Academic Press Inc.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 3, Issue 2
1 Mar 1967
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phosphofructokinase from the Liver Fluke Fasciola hepatica
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Phosphofructokinase from the Liver Fluke Fasciola hepatica

DEBORAH BENNETT STONE and TAG E. MANSOUR
Molecular Pharmacology March 1, 1967, 3 (2) 177-187;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Phosphofructokinase from the Liver Fluke Fasciola hepatica

DEBORAH BENNETT STONE and TAG E. MANSOUR
Molecular Pharmacology March 1, 1967, 3 (2) 177-187;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • EIPA, HMA and SMN2 gene regulation
  • Clc-2 has minor role in intestinal Cl- secretion
  • Resveratrol acts as an NR4A1 antagonist in lung cancer.
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics